• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Executive VP and CFO Steele Barry G bought $17,280 worth of shares (3,000 units at $5.76), increasing direct ownership by 4% to 76,887 units (SEC Form 4)

    5/14/25 7:45:34 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care
    Get the next $INFU alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Steele Barry G

    (Last) (First) (Middle)
    C/O INFUSYSTEM HOLDINGS, INC.
    3851 WEST HAMLIN ROAD

    (Street)
    ROCHESTER HILLS MI 48309

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    InfuSystem Holdings, Inc [ INFU ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Executive VP and CFO
    3. Date of Earliest Transaction (Month/Day/Year)
    05/14/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 73,887(1) D
    Common Stock 05/14/2025 P 3,000 A $5.76(2) 76,887 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This total includes an additional 3,692 shares acquired recently through the Company's Employee Stock Purchase Plan
    2. The price reported in Column 4 is a weighted average price. These shares reported herein were purchased in multiple transactions. The reporting person undertakes to provide to the Issuer, and security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
    Remarks:
    /s/ Kevin Whitman, Attorney-in-Fact for Barry G. Steele 05/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $INFU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INFU

    DatePrice TargetRatingAnalyst
    9/26/2024$13.00Buy
    B. Riley Securities
    More analyst ratings

    $INFU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InfuSystem Reports First Quarter 2025 Financial Results

      Record Net Revenues of $34.7 million Representing 9% Growth from the Prior Year Net loss of $0.3 million Adjusted EBITDA (non-GAAP) of $6.3 million, up 64% Adjusted EBITDA (non-GAAP) margin expanded by 6.2% to 18.2% Stock Repurchases totaled approximately $3.0 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2025. 2025 First Quarter Overview: Net revenues totaled $34.7 million, an increase of 9% vs. prior year. Patient Services net rev

      5/8/25 6:30:00 AM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • InfuSystem to Report First Quarter 2025 Financial Results on May 8, 2025

      Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue first quarter 2025 financial results on Thursday, May 8, 2025, before the market opens. The Company will also conduct a conference call for all interested parties on Thursday, May 8, 2025 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the Investor

      5/1/25 6:30:00 AM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • InfuSystem Announces CEO Transition; Carrie Lachance to Become Chief Executive Officer

      The Company Reaffirms Full Year 2025 Guidance: Revenue Growth of 8-10% and Adjusted EBITDA (non-GAAP) margin greater than 18.8% InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Richard DiIorio will be stepping down as the Company's Chief Executive Officer, effective May 19, 2025. Concurrently, the Company announced that Carrie Lachance, the Company's President and Chief Operating Officer, and a member of the Company's board of directors, will assume the role of Chief Executive Officer effective May 19

      4/1/25 6:30:00 AM ET
      $INFU
      Medical/Dental Instruments
      Health Care

    $INFU
    SEC Filings

    See more
    • InfuSystems Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

      5/9/25 4:12:35 PM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by InfuSystems Holdings Inc.

      10-Q - InfuSystem Holdings, Inc (0001337013) (Filer)

      5/8/25 1:12:42 PM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • InfuSystems Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

      5/8/25 6:27:27 AM ET
      $INFU
      Medical/Dental Instruments
      Health Care

    $INFU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $INFU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on InfuSystem with a new price target

      B. Riley Securities initiated coverage of InfuSystem with a rating of Buy and set a new price target of $13.00

      9/26/24 7:35:18 AM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • Northland Capital initiated coverage on InfuSystem with a new price target

      Northland Capital initiated coverage of InfuSystem with a rating of Outperform and set a new price target of $27.00

      4/26/21 8:42:07 AM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • Executive VP and CFO Steele Barry G bought $17,280 worth of shares (3,000 units at $5.76), increasing direct ownership by 4% to 76,887 units (SEC Form 4)

      4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

      5/14/25 7:45:34 PM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Dilorio Richard exercised 25,000 shares at a strike of $2.60 and covered exercise/tax liability with 17,976 shares, increasing direct ownership by 2% to 423,683 units (SEC Form 4)

      4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

      3/11/25 7:46:29 PM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • Director Shuda Scott disposed of 42,241 shares (SEC Form 4)

      4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

      12/6/24 6:18:28 PM ET
      $INFU
      Medical/Dental Instruments
      Health Care

    $INFU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by InfuSystems Holdings Inc.

      SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

      12/9/24 6:38:13 PM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by InfuSystems Holdings Inc.

      SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

      12/6/24 5:07:04 PM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by InfuSystems Holdings Inc.

      SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

      9/24/24 2:06:02 PM ET
      $INFU
      Medical/Dental Instruments
      Health Care

    $INFU
    Financials

    Live finance-specific insights

    See more
    • InfuSystem Reports First Quarter 2025 Financial Results

      Record Net Revenues of $34.7 million Representing 9% Growth from the Prior Year Net loss of $0.3 million Adjusted EBITDA (non-GAAP) of $6.3 million, up 64% Adjusted EBITDA (non-GAAP) margin expanded by 6.2% to 18.2% Stock Repurchases totaled approximately $3.0 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2025. 2025 First Quarter Overview: Net revenues totaled $34.7 million, an increase of 9% vs. prior year. Patient Services net rev

      5/8/25 6:30:00 AM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • InfuSystem to Report First Quarter 2025 Financial Results on May 8, 2025

      Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue first quarter 2025 financial results on Thursday, May 8, 2025, before the market opens. The Company will also conduct a conference call for all interested parties on Thursday, May 8, 2025 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the Investor

      5/1/25 6:30:00 AM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2024

      Full Year 2024 vs. Full Year 2023: Record Net Revenues: $134.9 million, a 7% increase Patient Services Revenue: $80.4 million - Device Solutions Revenue: $54.5 million, increases of 5% and 11% Adjusted EBITDA (non-GAAP): $25.3 million, a 13% increase Record Operating Cash Flow: $20.5 million, an 82% increase InfuSystem Holdings, Inc. (NYSE:INFU), ("InfuSystem" or the "Company"), a leading national healthcare service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter Overview: Net revenues totaled $33.8 million, an in

      3/4/25 6:30:00 AM ET
      $INFU
      Medical/Dental Instruments
      Health Care

    $INFU
    Leadership Updates

    Live Leadership Updates

    See more
    • InfuSystem Announces CEO Transition; Carrie Lachance to Become Chief Executive Officer

      The Company Reaffirms Full Year 2025 Guidance: Revenue Growth of 8-10% and Adjusted EBITDA (non-GAAP) margin greater than 18.8% InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Richard DiIorio will be stepping down as the Company's Chief Executive Officer, effective May 19, 2025. Concurrently, the Company announced that Carrie Lachance, the Company's President and Chief Operating Officer, and a member of the Company's board of directors, will assume the role of Chief Executive Officer effective May 19

      4/1/25 6:30:00 AM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • InfuSystem Appoints Ronald Hundzinski to the Board of Directors

      InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of Ronald Hundzinski, as an independent director to InfuSystem's Board of Directors, effective November 12, 2024. Mr. Hundzinski will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2025. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Ron to InfuSystem's Board. He adds both accounting and finance depth to our oversight and committee work and

      11/18/24 9:15:00 AM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • InfuSystem Appoints R. Rimmy Malhotra to the Board of Directors

      InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of R. Rimmy Malhotra, a new independent director to InfuSystem's Board of Directors, effective September 20, 2022. Mr. Malhotra will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2023. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Rimmy as a new independent director on InfuSystem's Board. Rimmy first invested in the Company in 2012, and has

      9/23/22 4:05:00 PM ET
      $INFU
      Medical/Dental Instruments
      Health Care

    $INFU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive VP and CFO Steele Barry G bought $17,280 worth of shares (3,000 units at $5.76), increasing direct ownership by 4% to 76,887 units (SEC Form 4)

      4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

      5/14/25 7:45:34 PM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • Director Eichenbaum Kenneth D. bought $23,560 worth of shares (4,000 units at $5.89) (SEC Form 4)

      4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

      9/25/24 6:19:48 PM ET
      $INFU
      Medical/Dental Instruments
      Health Care
    • Boyd Ralph F Jr bought $28,520 worth of shares (4,000 units at $7.13), increasing direct ownership by 200% to 6,000 units (SEC Form 4)

      4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

      5/23/24 6:07:25 PM ET
      $INFU
      Medical/Dental Instruments
      Health Care